top of page

Mapping autism spectrum disorder protein interactions with the director of UCSF's QBI

blonca9
Dec 4, 2023
1 min read

Nevan Krogan, Director of the Quantitative Biosciences Institute at UCSF, expands on work posted to bioRxiv today showing how mapping protein-protein interactions involving 100 autism spectrum disease risk genes could advance the understanding of autism biology.

Link: A foundational atlas of autism protein interactions reveals molecular convergence

This work was led by Dr. Krogan and the following collaborators:

Matthew State - Department of Psychiatry and Behavioral Sciences at the Weill Institute for Neurosciences at UCSF

Jeremy Willsey - Calico Life Sciences

Tomasz Nowakowski - Departments of Neurological Surgery and Anatomy at UCSF

Recent Posts

See All

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions

Jefferies London: Medicxi announced a €500 million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech

Jefferies London: Jefferies Chairman of Global Healthcare Philip Ross discusses the environment for biotech and deals

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate